Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ãµµ ÃéÀå¾Ï¿¡¼­ ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µÀÇ ÀÓ»óÀû¿ë Clinical Application of FDG-PET in Biliary-pancreatic Malignancy

´ëÇÑ¿Ü°úÇÐȸÁö 2003³â 65±Ç 1È£ p.61 ~ 68
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚÀ±Âù/ Park YC ±è¼±È¸/À±À¯¼®/¾È¿µÁØ/ÀåÁø¿µ/±èÀ¯°æ/Á¤Áرâ/ÀÌ°Ç¿í/¹Ú¿ëÇö/ Kim SW/Yoon YS/Ahn YJ/Jang JY/Kim YK/Jung JK/Lee KU/Park YH

Abstract


Purpose: This study was done to review our clinical experience of fluorodeoxyglucose (FDG)-position emission tomography (PET) in billiary-pancreatic malignancies, and evaluated its diagnostic accuracy and usefulness.
Methods: FDG-PET was performed in 15 patients with biliary-pancreatic malignancies, to determine the extent of the disease (n=9) and to detect the recurrence (n=6).
Results: Of the 9 patients with a suspected loco-regional spread, 6 patients were disclosed by FDG-PET as having multiple metastasis to the regional lymph nodes and extraperitoneal organs, but the other 3 showed no evidence of regional or distant metastasis. Thus, FDG-PET performed preoperatively to estimate the extent of the disease, showed sensitivity and specificity of 100%, respectively. However, for the detection of a recurrent disease only 3 out of 5 with recurrent diseases were detected by FDG-PET (sensitivity: 60%). FDG-PET revealed one suspected recurrent lesion, but a computed tomography (CT) scan showed no evidence of a recurrence. Due to the 2 false-negative results, the overall sensitivity and specificity of this study were 81.8 (9/11) and 100% (4/4), respectively.
Conclusion: Unnecessary surgical procedures were avoided in 6 cases, and 3 curative surgeries aborted through the use of FDG-PET. Despite the lack of cases, FDG-PET was useful in estimating the extent of a disease, but was unsatisfactory in detecting a recurrent disease compared to CT. Coupled with conventional imaging, FDG-PET may also provide more helpful information for biliary-pancreatic malignancies as well.

Å°¿öµå

PET; Staging; Recurrence; ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ; º´±â Áø´Ü; Àç¹ß

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS